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ABSTRACT 
 
Abdominal obesity is associated with blunted growth hormone (GH) secretion. GH 
treatment in abdominally obese men reduces visceral adipose tissue (VAT) and 
improves the metabolic profile.  
The aim of this study was to investigate alterations in the GH-IGF-1 axis in 
postmenopausal women and to study the effects of GH treatment on abdominal 
obesity, insulin resistance and other metabolic alterations associated with the 
metabolic syndrome. Gender differences in the response to GH treatment were also 
investigated. 
Forty abdominally obese women participated in a randomized, placebo controlled 
study. The 12-month GH treatment reduced VAT, increased thigh muscle area and 
reduced total and LDL-cholesterol as compared with placebo. Insulin sensitivity was 
increased at 12 months as compared with baseline values within the GH-treated 
group. 
There was a reduction in serum CRP and IL-6 concentrations after six and 12 months 
in the GH-treated women as compared with placebo. The reduction in CRP and IL-6 
was associated with a reduction in VAT and hepatic fat content, as well as an increase 
in serum IGF-1 levels. No significant effect was seen on markers of endothelial 
dysfunction: sE-selectin, VCAM-1, ICAM-1 or MMP-9. These findings suggest that 
GH exerts an attenuating effect on the state of chronic inflammation associated with 
the metabolic syndrome.  
A comparative study of postmenopausal women and middle-age men with abdominal 
obesity demonstrated that GH reduced VAT and increased thigh muscle mass more 
markedly in men as compared with women.  
In a cross-sectional study of postmenopausal abdominally obese women an 
independent, negative association between pulsatile GH secretion and intermuscular 
AT, and between basal GH secretion and VAT was shown. These findings suggest 
that the interactions between fat mass and the somatotropic axis are depot-dependent.  
In conclusion, these studies have shown that GH intervention improves the 
cardiovascular risk profile in abdominally obese postmenopausal women and that the 
interaction between fat mass and GH secretion seem to be depot-dependent. Men are 
more responsive to the lipolytic action of GH in VAT than women. Low GH secretion 
may have a role in the metabolic abnormalities associated with the metabolic 
syndrome. 
 
 
